Literature DB >> 7846738

A sensitive radioimmunoassay for fludrocortisone in human plasma.

V P Mitsky1, R J Workman, W E Nicholson, J Vernikos, R M Robertson, D Robertson.   

Abstract

Fludrocortisone has been a mainstay of therapy for orthostatic hypotension for many years. Clinical experience suggests that there exists a substantial interindividual variation in responsiveness to the drug. To assess this, we have developed an assay that permits measurement of the low concentrations of fludrocortisone found in human plasma. Fludrocortisone was detected by radioimmunoassay. A polyclonal rabbit antibody, raised against dexamethasone which cross-reacts strongly with fludrocortisone, was reacted with either standard or unknown samples in the presence of [125I]fludrocortisone-3-TyrNH2 (synthesized by coupling tyrosine amide to fludrocortisone-3-oxime and iodinating with chloramine T oxidation). The ED10, ED50, and ED80 were 0.34, 5.0, and 30 ng/mL of plasma, respectively. The cross reactivity with other 9-fluorinated steroids was found as follows: dexamethasone, 340%; betamethasone, 230%; and triamicinolone, 8%. To preclude an erroneous result, subjects who were pregnant or receiving any steroid medication were excluded from the study. The percent cross-reactivity with the main naturally occurring steroids was as follows: 11-desoxycortisol 3.2%, cortisol 1.1%, DOC 0.3%, pregnenolone 0.1%, corticosterone 0.06%, progesterone 0.05%, and aldosterone < 0.05%. The only compound with potential for interference, because of its high level in the circulation in the early morning, was cortisol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Keywords:  NASA Center HQS; NASA Discipline Regulatory Physiology; Non-NASA Center

Mesh:

Substances:

Year:  1994        PMID: 7846738     DOI: 10.1016/0039-128x(94)90074-4

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  4 in total

Review 1.  New trends in the treatment of orthostatic hypotension.

Authors:  J Jordan
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.

Authors:  Noureddine Hamitouche; Emmanuelle Comets; Mégane Ribot; Jean-Claude Alvarez; Eric Bellissant; Bruno Laviolle
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

3.  Pharmacokinetics of oral fludrocortisone in septic shock.

Authors:  Andrea Polito; Noureddine Hamitouche; Mégane Ribot; Angelo Polito; Bruno Laviolle; Eric Bellissant; Djillali Annane; Jean-Claude Alvarez
Journal:  Br J Clin Pharmacol       Date:  2016-08-22       Impact factor: 4.335

4.  Mineralocorticoid receptor signaling reduces numbers of circulating human naïve T cells and increases their CD62L, CCR7, and CXCR4 expression.

Authors:  Luciana Besedovsky; Barbara Linz; Jan Born; Tanja Lange
Journal:  Eur J Immunol       Date:  2014-04-10       Impact factor: 5.532

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.